Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases

Physical Medicine and Rehabilitation Clinics of North America

Volumn 23, Issue 3, 2012, Pages 495-563

  McDonald, Craig M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnostic evaluation; History; Motor neuron disease; Myopathy; Neuromuscular disease; Neuromuscular junction; Neuropathy; Physical examination

Indexed keywords

ACQUIRED NEUROMUSCULAR DISEASE; ANAMNESIS; ANTERIOR HORN CELL DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; EARLY DIAGNOSIS; ELECTROMYOGRAM; FAMILY HISTORY; FUNCTIONAL ASSESSMENT; GENETIC DISORDER; HEALTH CARE COST; HEREDITARY NEUROMUSCULAR DISEASE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MOLECULAR GENETICS; MOTOR NEURON DISEASE; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCULOSKELETAL SYSTEM; NERVE BIOPSY; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; NEUROMUSCULAR JUNCTION DISORDER; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL LABORATORY TECHNIQUES; COGNITION DISORDERS; FRIEDREICH ATAXIA; HUMANS; MEDICAL HISTORY TAKING; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR ATROPHY, SPINAL; MUSCULAR DYSTROPHIES; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASES; NEUROMUSCULAR JUNCTION DISEASES; PEDIGREE; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL EXAMINATION; SPINOCEREBELLAR ATAXIAS;

EID: 84865560619     PISSN: 10479651     EISSN: 15581381     Source Type: Journal    
DOI: 10.1016/j.pmr.2012.06.011     Document Type: Review

References (96)

1. Neuromuscular disorders: gene location. Neuromuscul Disord 2006, 16(1):64-90.
2. Gospe S.M., Lozaro R.P., Lava N.S., et al. Familial X-linked myalgia and cramps: a non-progressive myopathy associated with a deletion in the dystrophin gene. Neurology 1989, 39:1277-1280.
3. Mills K.R., Edwards R.H. Investigative strategies for muscle pain. J Neurol Sci 1983, 58:73.
4. Cros D., Harnden P., Pellisier J.F., et al. Muscle hypertrophy in Duchenne muscular dystrophy: a pathological and morphometric study. J Neurol 1989, 236:43-47.
5. Reimers C.D., Schlotter B., Eicke B.M., et al. Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. J Neurol Sci 1996, 143(1-2):46-56.
6. Pradhan S. New clinical sign in Duchenne muscular dystrophy. Pediatr Neurol 1994, 11:298-300.
7. Ianassecu V. Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve 1995, 18:267-275.
8. Sigford B. Psychosocial, cognitive and educational issues in neuromuscular disease. Phys Med Rehabil Clin N Am 1998, 9(1):249-270.
9. Meyerson M.D., Lewis E., ILL K. Facioscapulohumeral muscular dystrophy and accompanying hearing loss. Arch Otolaryngol 1984, 110(4):261-266.
10. Padberg G.W., Brouwer O.F., deKeizer R.J., et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995, 2:S73-S80.
11. Verhagen W.I., Huygen P.L., Padberg G.W. The auditory, vestibular and oculomotor system in facioscapulohumeral dystrophy. Acta Otolaryngol Suppl 1995, 520(Pt 1):140-142.
12. Guenther U.P., Handoko L., Laggerbauer B., et al. IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1). Hum Mol Genet 2009, 18(7):1288-1300.
13. Young I.D., Harper P.S. Hereditary distal spinal muscular atrophy with vocal cord paralysis. J Neurol Neurosurg Psychiatry 1980, 43:413-418.
14. Innaccone S.T., Browne R.H., Samaha F.J., et al. DCN/SMA Group: prospective study of spinal muscular atrophy before age 6 years. Pediatr Neurol 1993, 9:187-193.
15. Munsat T.L., Davies K.E. Meeting report: international SMA consortium meeting. Neuromuscul Disord 1992, 2:423-428.
16. Muntoni F., Valero de Bernabe B., Bittner R., et al. 114th ENMC International Workshop on Congenital Muscular Dystrophy (CMD) 17-19 January 2003, Naarden, The Netherlands: (8th Workshop of the International Consortium on CMD; 3rd Workshop of the MYO-CLUSTER project GENRE). Neuromuscul Disord 2003, 13(7-8):579-588.
17. Parano E., Fiumara A., Falsaperla R., et al. A clinical study of childhood spinal muscular atrophy in Sicily: a review of 75 cases. Brain Dev 1994, 16(2):104-107.
18. Bach J.R., Want T.G. Noninvasive long-term ventilatory support for individuals with spinal muscular atrophy and functional bulbar musculature. Arch Phys Med Rehabil 1995, 76:213.
19. Koga Y., Akita Y., Nishioka J., et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005, 64(4):710-712.
20. Arkin A.M. Absolute muscle power: the internal kinesiology of muscle, thesis 1939, Department of Orthopedic Surgery. State University of Iowa, Ames, (IA).
21. Von Recklinghausen H. Gliedermechanik and Lahmungsprothesen 1920, Springer-Verlag, Berlin.
22. Kilmer D.D., McCrory M.A., Wright N.C., et al. The effect of high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1994, 75:560-563.
23. Aitkens S., Lord J., Bernauer E., et al. Relationship of manual muscle testing to objective strength measurements. Muscle Nerve 1989, 12:173-177.
24. Lord J.P., Aitkens S., McCrory M., et al. Isometric and isokinetic measurement of hamstring and quadriceps strength. Arch Phys Med Rehabil 1992, 73:324-330.
25. Aitkens S.G., McCrory M.A., Kilmer D.D., et al. Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1993, 74:711-715.
26. Carter G.T., Abresch R.T., Fowler W.M., et al. Profiles of neuromuscular diseases: hereditary motor and sensory neuropathy, types I and II. Am J Phys Med Rehabil 1995, 749(Suppl):S140-S149.
27. Fowler W.M., Abresch R.T., Aitkens S., et al. Profiles of neuromuscular diseases: design of the protocol. Am J Phys Med Rehabil 1995, 74(Suppl):S62-S69.
28. Fowler W.M., Gardner G.W. Quantitative strength measurements in muscular dystrophy. Arch Phys Med Rehabil 1968, 48:629-644.
29. Johnson E.R., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases: myotonic dystrophy. Am J Phys Med Rehabil 1995, 74(Suppl):S104-S116.
30. Kilmer D.D., Abresch R.T., McCrory M.A., et al. Profiles of neuromuscular diseases: facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 1995, 74:S131-S139.
31. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases: Becker's muscular dystrophy. Am J Phys Med Rehabil 1995, 74(Suppl):S70-S92. S93-103.
32. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74(Suppl):S70-S92.
33. McDonald C.M., Jaffe K.M., Shurtleff D.B. Clinical assessment of muscle strength in children with meningomyelocele: accuracy and stability of measurements over time. Arch Phys Med Rehabil 1986, 67:855-861.
34. Eng G.D., Binder H., Koch B. Spinal muscular atrophy: experience in diagnosis and rehabilitation in management of 60 patients. Arch Phys Med Rehabil 1984, 65:549-553.
35. Munsat T.L. Standardized forearm ischemic exercise test. Neurology 1970, 20:1171.
36. Munsat T.L. Workshop report: international SMA collaboration. Neuromuscul Disord 1991, 1:81.
37. de Greef J.C., Lemmers R.J.L.F., Camaño P., et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010, 75:1548-1554.
38. Coleman R.A., Stajich J.M., Pact V.W., et al. The ischemic exercise test in normal adults and in patients with weakness and cramps. Muscle Nerve 1986, 9:216.
39. Sinkeler S.P., Daanen H.A., Wevers R.A., et al. The relation between blood lactate and ammonia in ischemic handgrip exercise. Muscle Nerve 1985, 8:523.
40. Fischer A.Q., Carpenter D.W., Hartlage P.L., et al. Muscle imaging in neuromuscular disease using computerized real-time sonography. Muscle Nerve 1988, 11:270-275.
41. Heckmatt J.Z., Dubowitz V. Ultrasound imaging and directed needle biopsy in the diagnosis of selective involvement in neuromuscular disease. J Child Neurol 1987, 2:205-213.
42. Heckmatt J.Z., Leeman S., Dubowitz V. Ultrasound imaging in the diagnosis of muscle disease. J Pediatr 1982, 101:656-660.
43. Heckmatt J.Z., Pier N., Dubowitz V. Real-time ultrasound imaging of muscles. Muscle Nerve 1988, 11:56-65.
44. Zaidman C.M., Connolly A.M., Malkus E.C., et al. Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 2010, 20(12):805-809.
45. Finanger E.L., Russman B., Forbes S.C., et al. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012, 23:1-10.
46. Huang Y., Majumdar S., Genant H.K., et al. Quantitative MR relaxometry study of muscle composition and function in Duchenne muscular dystrophy. J Magn Reson Imaging 1994, 4(1):59-64.
47. Liu G.C., Jong Y.J., Chiang C.H., et al. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology 1993, 186(2):475-480.
48. Liu M., Chino N., Ishihara T. Muscle damage progression in Duchenne muscular dystrophy evaluated by a new quantitative computed tomography method. Arch Phys Med Rehabil 1993, 74(5):507-514.
49. Tomasová Studynková J., Charvát F., Jarosová K., et al. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2007, 46(7):1174-1179.
50. Topalogu H., Gucuyener K., Yalaz K., et al. Selective involvement of the quadriceps muscle in congenital muscular dystrophies: an ultrasonographic study. Brain Dev 1992, 14:84-87.
51. Skalsky A.J., Han J.J., Abresch R.T., et al. Regional and whole-body dual-energy X-ray absorptiometry to guide treatment and monitor disease progression in neuromuscular disease. Phys Med Rehabil Clin N Am 2012, 23(1):67-73. x. Review.
52. Carter G.T., Abresch R.T., Fowler W.M., et al. Profiles of neuromuscular diseases: spinal muscular atrophy. Am J Phys Med Rehabil 1995, 74(Suppl):S150-S159.
53. McDonald C.M., Johnson E.R., Abresch R.T., et al. Profiles of neuromuscular diseases: limb-girdle syndromes. Am J Phys Med Rehabil 1995, 74(Suppl):S117-S130.
54. Norris F., Sheperd R., Denys E., et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993, 118(1):48-55.
55. Pradas J., Finison L., Andres P.L., et al. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993, 43(4):751-755.
56. Ringel S.P., Murphy J.R., Alderson M.K., et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993, 43(7):1316-1322.
57. Sharma K.R., Miller R.G. Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis. Muscle Nerve 1996, 19:1391-1400.
58. Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Genet 2006, 7:710-723.
59. Phoenix J., Betal D., Roberts N., et al. Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Muscle Nerve 1996, 19(3):302-310.
60. Shaw C.E., Al-Chalabi A. Susceptibility genes in sporadic ALS: separating the wheat from the chaff by international collaboration. Neurology 2006, 67:738-739.
61. Sobue I., Saito N., Iida M., et al. Juvenile type of distal and segmental muscular atrophy of the upper extremities. Ann Neurol 1978, 3:429-432.
62. Suput D., Zupan A., Sepe A., et al. Discrimination between neuropathy and myopathy by use of magnetic resonance imaging. Acta Neurol Scand 1993, 87(2):118-123.
63. Andersen P.M., Nilsson P., Keranen M.-L., et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997, 120:1723-1737.
64. Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
65. Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009, 4:3.
66. Zerres K., Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Arch Neurol 1995, 52:518.
67. Parsons D.W., McAndrew P.E., Iannaccone S.T., et al. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet 1998, 63(6):1712-1723.
68. Swoboda K.J., Prior T.W., Scott C.B., et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005, 57(5):704-712.
69. Swash M., Brown M.M., Thakkar C. CT muscle imaging and the clinical assessment of neuromuscular disease. Muscle Nerve 1995, 18(7):708-714.
70. Zerres K., Wirth B., Rudnik-Schöneborn S. Spinal muscular atrophy-clinical and genetic correlations. Neuromuscul Disord 1997, 7(3):202-207.
71. Pineda M., Arpa J., Montero R., et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 2008, 12(6):470-475.
72. Jones H.R., Bradshaw D.Y. Guillain-Barré syndrome and plasmapheresis in childhood. Ann Neurol 1991, 29:688.
73. Ouvrier R.A., McLeod J.G., Pollard J.D. Acute inflammatory demyelinating polyradiculoneuropathy. Peripheral neuropathy in childhood. International Review of Child Neurology Series 1999, Mac Keith Press, London.
74. Bradshaw D.Y., Jones H.R. Guillain-Barré syndrome in children: clinical course, electrodiagnosis and prognosis. Muscle Nerve 1992, 15(4):500.
75. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation in Duchenne dystrophy. 2. Determination of the " power" of therapeutic trials based on the natural history. Muscle Nerve 1983, 6:91-103.
76. Epstein M.A., Sladky J.T. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990, 28:65.
77. Lamont P.J., Johnston H.M., Berdoukas V.A. Plasmapheresis in children with Guillain-Barré syndrome. Neurology 1991, 41(12):1928.
78. Lavenstein B.L., Shin W., Watkin T., et al. Four-year followup study of use of IVIG in childhood acute inflammatory demyelinating polyneuropathy (GBS). Neurology 1994, 44:A169.
79. Shahar E., Murphy E.G., Roifman C.M. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr 1990, 116(1):141.
80. Tekgul H., Serdaroglu G., Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barré syndrome in children. Pediatr Neurol 2003, 28(4):295-299.
81. Barisic N., Claeys K.G., Sirotković-Skerlev M., et al. Charcot-Marie-Tooth disease: a clinico-genetic confrontation. Ann Hum Genet 2008, 72(Pt 3):416-441. Review.
82. Carter G.T., Weiss M.D., Han J.J., et al. Charcot-Marie-Tooth disease. Curr Treat Options Neurol 2008, 10(2):94-102.
83. Hoffman W.H., Hat Z.H., Frank R.N. Correlates of delayed motor nerve conduction and retinopathy in juvenile-onset diabetes mellitus. J Pediatr 1983, 102:351.
84. Emery A.E. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991, 1:19.
85. Muchir A., Worman H.J. Emery-Dreifuss muscular dystrophy. Curr Neurol Neurosci Rep 2007, 7(1):78-83.
86. Voit T., Krogmann O., Lennard H.G., et al. Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropediatrics 1988, 19:62.
87. D'Amico A., Bertini E. Congenital myopathies. Curr Neurol Neurosci Rep 2008, 8(1):73-79. Review.
88. Van den Hout J.M., Kamphoven J.H., Winkel L.P., et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004, 113(5):e448-e457.
89. van Engelen B.G., Eymard B., Wilcox D. 123rd ENMC International Workshop: management and therapy in myotonic dystrophy, 6-8 February 2004, Naarden, The Netherlands. Neuromuscul Disord 2005, 15(5):389-394.
90. Udd B., Meola G., Krahe R., et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006, 16(6):403-413.
91. Askanas V., Engel W.K. Inclusion body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007, 19(6):550-559.
92. Okumiya T., Keulemans J.L., Kroos M.A., et al. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab 2006, 88(1):22-28.
93. Winchester B., Bali D., et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. J Mol Genet Metab 2008, 93(3):275-281. Pompe Disease Diagnostic Working Group.
94. Winkel L.P., Van den Hout J.M., Kamphoven J.H., et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004, 55(4):495-502.
95. Roe C.R., Yang B.Z., Brunengraber H., et al. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008, 71(4):260-264.
96. Bonnefont J.P., Bastin J., Behin A., et al. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009, 360(8):838-840.